Home
overview

SMi is proud to present its 3rd Annual Drug Discovery Chemistry conference on the 18th-19th March 2019 in London.


The drug discovery field is undergoing dramatic change. There is currently a reduced output of new medicines due to challenges in R&D, pricing pressures and regulations. While these challenges are slowing progress, demand for new, more effective medicines are steadily growing. However, new technologies have allowed for the drug discovery process to overall become more streamlined and cost-efficient, and scientific advances have made the identification of novel drug targets, modalities, and therapeutic areas to be recognised. This presents a new opportunity for the development of novel medicines and technologies within the pharmaceutical market.


SMi group’s 3rd annual Drug Discovery Chemistry conference aims to discuss emerging techniques, potential drug targets, and advances in the drug discovery field that are driving the pharmaceutical industry into a new era of medicines and therapeutics. This conference aims to provide insight into how these developments can be best utilised in the commercial setting.


Join us in London, March 2019, as we discuss the latest developments in the field of Drug Discovery Chemistry. Network with industry experts, gain insight into the latest technological developments and how these are being utilised within the pharmaceutical industry, discuss the potential of novel drug modalities, the use of AI in drug discovery and the latest medicinal chemistry techniques and how these can be brought into the commercial market.

  • Discuss latest advances in medicinal chemistry techniques and how these can be implemented in the commercial space of drug discovery.
  • Learn about protein degradation in drug discovery with the utilisation of PROTACs
  • Hear about PPIs and how protein-protein interactions are being targeted in drug discovery
  • Gain insight into the potential of Macrocycles in targeting difficult genomic targets 
  • Discuss the uses and advances in AI in drug discovery and the potential for the future
  • Hear about how the pharmaceutical industry are making use of AI currently

Abbvie Deutschland GmbH & Co KG; ABX-CRO; Angelini s.p.a.; AstraZeneca; Boehringer Ingelheim ; Fundació Sant Joan de Déu; GSK; Health Protection Agency; J and J; Janssen (Johnson&Johnson); Johnson & Johnson; mayer brown llp; MHRA; Novo Nordisk A/S; Orion Pharma; Orphazyme A/S; Otsuka Europe Development and Commercialisation Ltd; Paediatric Research Consultancy and Please Read Carefully Lay Language Communications; Pfizer Inc.; Quotient Sciences; Roche Pharma Schweiz AG; Roche Products Ltd; Saint Joan de Deu Research Foundation; Sanofi; SynteractHCR; Takeda; The Royal Liverpool Children's Hospital trust; UCB Pharma; University of Liverpool; Vifor (International) Ltd;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Roderick  Hubbard

Roderick Hubbard , Senior Fellow, University of York & Vernalis Research Ltd
View Bio

9:10 Winning for the future: strategies to deliver small molecules

Tobias Gabriel

Tobias Gabriel, Head, External Science & Drug Discovery, Novartis Institutes for BioMedical Research, Inc.
View Bio

  • Utilising strategic medicinal chemistry techniques to optimise the small molecule drug discovery process
  • Implementation of faster screening and target validation techniques and its implications on the drug discovery process
  • Streamlining of the R&D process with medicinal chemistry techniques
  • 9:50 Protein degradation in drug discovery - PROTACs and its uses within the field

    Markus Queisser

    Markus Queisser , Scientific Leader, Glaxo Smith Kline
    View Bio

  • The emerging technique of utilising PROTACs to target proteins and its advantages in target validation
  • The prospects of using PROTACs in therapeutics
  • The limitations of PROTACs and how to utilise them in the clinic
  • IMiDs and molecular glues

     

  • 10:30 Morning Coffee

    11:00 Enabling drug discovery for challenging targets – Mcl-1 and Bcl-2

    Roderick  Hubbard

    Roderick Hubbard , Senior Fellow, University of York & Vernalis Research Ltd
    View Bio

    •     Enabling drug discovery against challenging targets
    •     The importance of biophysical methods in target evaluation and characterisation
    •     From fragment hits to clinical candidates
     

    11:40 Antibodies and their potential within drug discovery

    Andrew Popplewell

    Andrew Popplewell, Head Antibody Discovery, UCB
    View Bio

  •  Novel modalities of antibodies in drug discovery: antibody drug conjugates and novel scaffolds of Fc-regions with enhanced effector activities
  • Technological advances in antibody discovery, expression, engineering and its contribution to antibody candidate molecules
  • Drug conjugates and aspects of their design and delivery – linker strategies, bystander effects etc.
  • The future of antibodies in therapeutics.
     
  • 12:20 Networking Lunch

    13:20 Discovery of Risdiplam, a selective survival of Motor Neuron-2 (SMN2) gene splicing modifier for the treatment of Spinal Muscular Atrophy (SMA)

    Hasane Ratni

    Hasane Ratni, Expert Scientist, Roche Pharmaceuticals
    View Bio

  • Concept of gene splicing modulation
  • Medicinal chemistry optimization leading to the discovery of risdiplam
  • Selectivity (vs other genes) as a key aspect
  • Safety characterisation
     
  • 14:00 Macrocycles - their uses, advantages and synthesis for commercial use

    Helmut Thomas

    Helmut Thomas, President and CEO, Cylenium Pharma
    View Bio

  • Macrocycles as an emerging part of chemical space and it’s potential to drug difficult genomic targets
  • How the synthesis of Macrocycles using the Multicomponent Reaction Chemistry (MCR) can provide molecular diversity and complexity at low synthetic costs
  • Current technologies implemented at Cyclenium
  • The future in circumventing major permeability and bioavailability obstacles in macrocycle use
  • Examples of drug discovery with Cyclenium’s QUEST™ macrocycles on difficult targets
  • 14:40 DNA encoded libraries and their practical uses

    Frederic Berst

    Frederic Berst, Senior Investigator, Novartis
    View Bio

  • Discuss the design of DNA encoded libraries at NIBR
  • Insight into Novartis’ schemes for Innovation in DEL
  • Case study
     
  • 15:20 Afternoon Tea

    15:50 Important aspects of fragment based library design- Ro3 and Beyond

    Phil Cox

    Phil Cox, Senior Principal Research Scientist, Abbvie
    View Bio

  • Ro3 covers the idealized physicochemical property space of fragments but what other factors are important for fragment design?
  • What is the sweet spot for saturation (Fsp3) of fragments?
  • Shape-based considerations- flat, 3D, or somewhere in between?
  • Fragment follow-up: encoding chemistries into fragment libraries
  • Case study of how our newly designed fragments enabled a fragment to lead campaign in short order.
     
  • 16:30 NMR fragment screening in early stage drug discovery

    Christine Prosser

    Christine Prosser, Principal Scientist, UCB Celltech
    View Bio

  • Introduction to NMR screening methods – both ligand and protein observe
  • Practical considerations of NMR fragment screening
  • Confirmation and elaboration of NMR fragment hits
  • Case study: Combining NMR fragment screening and orthogonal screening techniques


     
  • 17:10 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Darren Green

    Darren Green, Director of Molecular Design, GlaxoSmithKline plc
    View Bio

    9:10 Chemical biology - new approaches to drug the undruggable

    Ulrich Schopfer

    Ulrich Schopfer, Head of Integrated Target & Lead Discovery, Novartis
    View Bio

    • New technologies
    • New modalities
    •  Where to play and how to win
       

    9:50 Computational chemogenomics and utilisation of AI

    Edgar Jacoby

    Edgar Jacoby, Senior Principal Scientist Computational Chemistry at Janssen, Johnson and Johnson
    View Bio

  • The future of Computational Chemogenomics – the genome wide search for druggable interactions
  • Efficient utilisation of AI within the computational chemogenomic space

  • Highlights from recent case studies

  • 10:30 Morning Coffee

    11:00 Arsenic Methyl Transferase and its potential role in CNS

    Roland Burli

    Roland Burli, Senior Director, Head of Medicinal Chemistry, Astrazeneca
    View Bio

  • Discovery of a form of arsenic methyl transferase (AS3MT) as a potential risk factor for schizophrenia
  • Molecular modelling, virtual screen, hit identification
  • The biological role of AS3MT – identification of potential interaction partners
     
  • 11:40 Using Artificial intelligence in early drug discovery

    Vivek Vishnudas

    Vivek Vishnudas, Sr Vice President Drug discovery & Platform Sciences, Berg LLC
    View Bio

  • Advances in how artificial intelligence can be used to identify druggable targets
  • The ability of AI to prioritise drug targets and it’s uses in preventing drug discovery failures
  • The opportunities of deep learning in the drug discovery process
     
  • 12:20 Networking Lunch

    13:20 Next generation drug discovery: Encoded Library Technology in Nanospheres

    James Dale

    James Dale, Senior Scientist and Head of Chemistry, Nanna Therapeutics
    View Bio

  • Nanna Therapeutic’s proprietary screening and AI platform (T.I.M.E.) to speed-up drug discovery
  • Encoded Library Technology in Nanospheres: Expanding the boundaries of bio-relevant chemical space
  • Highlights from recent case studies


     
  • 14:00 Utilising AI in structure based drug design and the implications of virtual screening

    Govinda  Bhisetti

    Govinda Bhisetti, Principal Investigator and Head of Computational Chemistry, Biogen
    View Bio

  • Overview of the quantum computing molecule comparison and its implications in speeding virtual screening process
  • The utilisation of machine learning models in ADME optimisation in design of drugs for neurodegenerative disorders
  • The role of computational techniques in streamlining structure-based drug design - a case study
  • 14:40 Afternoon Tea

    15:10 When the rubber hits the road: The application of AI across drug discovery

    Chris Tame

    Chris Tame, Research Leader, BenevolentAI
    View Bio

    The talk will focus on the application of AI to:
    • Target Identification
    • Medicinal Chemistry
    • Patient Stratification
     

    15:50 Machine learning for drug discovery

    Alexander Hillisch

    Alexander Hillisch, Director, Medicinal Chemistry, Bayer
    View Bio

  • The use of Machine Learning for ADME prediction
  • The utilisation of these outcomes in determining next steps in the drug discovery process
  • Case studies
  • 16:30 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Alexander Hillisch

    Alexander Hillisch

    Director, Medicinal Chemistry, Bayer
    Darren Green

    Darren Green

    Director of Molecular Design, GlaxoSmithKline plc
    Govinda  Bhisetti

    Govinda Bhisetti

    Principal Investigator and Head of Computational Chemistry, Biogen
    Hasane Ratni

    Hasane Ratni

    Expert Scientist, Roche Pharmaceuticals
    Helmut Thomas

    Helmut Thomas

    President and CEO, Cylenium Pharma
    Tobias Gabriel

    Tobias Gabriel

    Head, External Science & Drug Discovery, Novartis Institutes for BioMedical Research, Inc.
    Vivek Vishnudas

    Vivek Vishnudas

    Sr Vice President Drug discovery & Platform Sciences, Berg LLC

    Alexander Hillisch

    Director, Medicinal Chemistry, Bayer
    Alexander Hillisch

    Alexander Hillisch is a Director of Medicinal Chemistry and Head of Computational Chemistry at Bayer AG, Wuppertal, Germany. His team supports drug discovery in cardiology and ophthalmology indication areas with computational chemistry, chemoinformatics, in silico ADMET and structural bioinformatics techniques.
    From 1998 to 2003 he headed a research group at EnTec GmbH, Jena, Germany, a subsidiary of Schering AG, Berlin. There he was project manager in preclinical research and involved in the computer-aided design and pharmacological characterization of drugs against gynecological diseases and cancer.
    He conducted his Ph.D. thesis at the Institute of Molecular Biotechnology (IMB), Jena in the area of biophysics (NMR, FRET) and molecular modeling. Alexander Hillisch received his Ph.D. in Biochemistry with Prof. Peter Schuster in 1998 and his diploma in Pharmacy in 1995 from the University of Vienna, Austria.
    He is author of 43 research papers, 61 patents and 2 books. Alexander teaches “Molecular pharmacology and Drug Design” at the University of Cologne from which he received a honorary professorship in 2010.
     

    Andrew Popplewell

    Head Antibody Discovery, UCB
    Andrew Popplewell

    Andrew Popplewell PhD

    Head, Antibody Discovery and Engineering, UCB Celltech.

    After studying for a BSc(Hons) at Edinburgh University and obtaining a PhD from Southampton University in protein engineering, Dr Popplewell held post-doctoral positions at both Edinburgh and Southampton before joining Celltech in 1993. During his 25 years at Celltech (since 2004 UCB Celltech), Dr Popplewell has played a role in developing their antibody humanisation and E. coli expression technologies and has worked on the approved medicines Cimzia and Besponsa, plus several other clinical candidates. He currently leads the V-Region Discovery and Engineering department, overseeing the identification, humanisation and characterisation of therapeutic antibodies and antibody research tools.
     

    Chris Tame

    Research Leader, BenevolentAI
    Chris Tame

    Chris joined BenevolentAI in December 2017 and currently leads multi-disciplinary teams in target identification and medicinal chemistry research areas. Prior to this, Chris worked at GSK for 10 years, initially as a medicinal chemist in the Respiratory group and later as a project leader in the Protein Degradation group. Chris graduated with a PhD in medicinal chemistry from the University of Strathclyde in 2014 under the guidance of Simon Peace and Craig Jamieson, where he developed isoform selective and orally bioavailable PI3K inhibitors and avb6 integrin antagonists

    Christine Prosser

    Principal Scientist, UCB Celltech
    Christine Prosser

    I joined UCB Celltech as a school leaver in 1999. In 2005 I gained a First Class Honours Degree in Chemistry from the University of Greenwich having studied part time whilst providing chromatography, mass spectrometry, purification and physchem support at UCB.
    In 2015 I completed a part time PhD at the University of Leicester in Protein NMR and Structural Biology and now have an Honorary Visiting Fellow position at Leicester.
    My responsibilities now include large molecule NMR support, fragment screening by NMR and coordination of the Leicester NMR and Antibody Assisted Drug Discovery collaborations.
     

    Darren Green

    Director of Molecular Design, GlaxoSmithKline plc
    Darren Green

    Darren Green is Director of Molecular Design, GlaxoSmithKline. Based at Stevenage, his group specialises in the application of computational chemistry, machine learning and chemoinformatics methods to drug discovery. Darren also leads the GSK-ex scientia collaboration.
    Darren has a PhD in Theoretical Chemistry from the University of Manchester and is a Fellow of the Royal Society of Chemistry.
     

    Edgar Jacoby

    Senior Principal Scientist Computational Chemistry at Janssen, Johnson and Johnson
    Edgar Jacoby

    Edgar Jacoby holds a Licence en Sciences Chimiques from Louvain and a Dr.rer.nat. in Computational Chemistry from the RWTH Aachen. After post-doctoral work in Molecular Biophysics at Harvard Medical School and The University of Chicago, he joined 1995 Servier as Cadre de Recherches in Molecular Modeling. 1999, he joined the Combinatorial Chemistry group at Novartis Central Technologies as Labhead for the in silico design of combinatorial compound libraries. From 2002-2012 he lead the Molecular and Library Informatics group in the Novartis Center of Proteomic Chemistry in Basel. In spring 2013, he joined Janssen Research & Development in Beerse as Senior Principal Scientist in Computational Chemistry.

    Frederic Berst

    Senior Investigator, Novartis
    Frederic Berst

    Frédéric Berst did his PhD in the group of Pr. Andrew Holmes at the University of Cambridge, UK, where he developed new strategies towards the solid-phase synthesis of cyclic tetrapeptoids. He then moved to the laboratory of Pr. Jonathan Ellman at the University of California, Berkeley, where he participated in the elaboration of new methods for protease substrate-activity-profiling. He then joined Novartis in late 2003 as a laboratory head in the combinatorial chemistry unit. After further scientific positions in Fragment-Based Drug Design and lead optimization programs against GPCR, kinase and PPI targets, he supervised the build-up of the NIBR DNA-Encoded Library (DEL) chemistry platform through a technology transfer from NuEvolution, a leading biotech in the field. As the DEL chemistry program team leader, his main responsibilities are the design and synthesis of DNA-encoded libraries, DEL chemistry and technology development, and screening campaign support.

     

    Govinda Bhisetti

    Principal Investigator and Head of Computational Chemistry, Biogen
    Govinda  Bhisetti

    Govinda Bhisetti is a Principal Investigator and Head of Computational Chemistry department at Biogen. Prior to Biogen, Govinda worked at Vertex Pharmaceuticals for 22 years where he led drug design efforts on several drug discovery projects.

    He is a co-inventor of three approved drugs, Agenerase, Lexiva, and Incivek. Govinda is a named inventor on 25 US patents and an author on 71 research papers.

    Govinda got his Ph. D. from Indian Institute of Science, Bangalore, and was a post-doctoral fellow at Scripps Research Institute, La Jolla, CA. His current activities include discovery of novel drugs for neurodegenerative and neuroinflammatory diseases.
     

    Hasane Ratni

    Expert Scientist, Roche Pharmaceuticals
    Hasane Ratni

    Dr H. Ratni is an Expert Scientist, Medicinal Chemistry, at F. Hoffmann-La Roche Ltd., Basel, Switzerland.
    He received his PhD at the University of Geneva and did a post-doc at Tokyo before joining F. Hoffmann-La Roche Ltd in 2001. His research has mainly been devoted to the areas of neuroscience (e.g. V1a receptor antagonist now in human clinical trials, phase II, for autism). In 2005, he participated in a secondment within the Roche group at Chugai Pharmaceutical Co. Ltd, Gotemba Japan. He was the chemistry discovery project leader of the SMN program aiming for a treatment for spinal muscular atrophy, now completing pivotal clinical trials in patients. His current focus is on gamma secretase modulator for Alzheimer disease.
    He is an author or co-author of more than 110 patents and publications. In 2014 he received the Roche Leo Sternbach Award for Innovation in Chemistry and in 2016 the Gold medal at the Roche Patent Inventor’s recognition event.
     

    Helmut Thomas

    President and CEO, Cylenium Pharma
    Helmut Thomas

    Co-founder, President, CEO and CSO of Cyclenium Pharma, a leader in drug discovery with small molecule macrocycles. Previously, Senior Vice President, Research and Non-clinical Development, at Tranzyme Pharma (2006 – 2013), Vice President, Development, with LymphoSign Inc. (2004-2006) and fourteen-year tenure with CIBA/Novartis Pharma, A.G. holding several senior management positions in R&D in Europe and the United States (1990-2003). Extensive and productive career in drug discovery and development, author of over 150 scientific articles, book chapters and abstracts, and co-inventor on numerous patents. Ph.D. in biochemistry and organic chemistry from the University of Hannover, Germany, and Board (ABT) certified toxicologist (DABT).

    James Dale

    Senior Scientist and Head of Chemistry, Nanna Therapeutics
    James Dale

    James has over 18 years’ experience in synthetic and medicinal chemistry, working in the Big Phrama and the Biotech sectors. During his time at Novartis, James worked on programmes focused on developing small molecule therapeutics in the areas of respiratory and gastrointestinal diseases and was lead chemist on number of Hit-2-Lead and Lead-Op campaigns. While at Proximagen, he led a team of scientists working on a CNS target with a novel mode of action. James is now heading the chemistry efforts at Nanna Therapeutics, utilising the proprietary integrated T.I.M.E platform and in particular Encoded Library Technology in Nanospheres in order to identity novel therapeutics across a breadth of therapeutic indications.

    Markus Queisser

    Scientific Leader, Glaxo Smith Kline
    Markus Queisser

    Markus got fascinated by the process of protein degradation early on during his Master’s thesis at Free University in Berlin, where he worked on proteasomal functions and ubiquitin-binding proteins. He further gained broad knowledge in respiratory diseases, inflammation and oncology while pursuing a Ph.D. in molecular biology and medicine of the lung in Germany and at Albert-Einstein College of Medicine in New York. He moved on to a postdoctoral fellowship at Northwestern University in Chicago, where in collaboration with Noble Laureate Aaron Ciechanover, he discovered a hypoxia-regulated ubiquitin-ligase. Prior joining GSK, he specialized in ubiquitin-ligase recruitment in ER-associated protein degradation at the Ludwig Institute for Cancer Research in Oxford. Currently, he is Scientific Leader within the Protein Degradation DPU, leading the technology branch.

    Phil Cox

    Senior Principal Research Scientist, Abbvie
    Phil Cox

    Phil Cox began his industrial career in 1997 with Oxford Asymmetry International (now Evotec) where he was a Project Leader in the Discovery Services Division working on multiple collaborations in both the Pharmaceutical and Agrochemical sectors. Phil then moved to Pharmacia, Skokie, where he was a member of the Parallel Medicinal Chemistry Group before transferring to Ann Arbor as part of the Pfizer acquisition in 2003. After the closure of Ann Arbor in 2007, Phil moved to Abbott Labs (now AbbVie Inc.) where he is currently a Senior Principal Research Scientist and chemistry group leader. In 2016 Phil was appointed an Adjunct Professor of Chemistry at Washington State University. Phil is an inventor on numerous patents spanning multiple therapeutic areas and has published articles in the areas of property-based design, fragment-based drug discovery, and compound file management.

    Roderick Hubbard

    Senior Fellow, University of York & Vernalis Research Ltd
    Roderick  Hubbard

    Rod Hubbard has been an academic at York for over 35 years working with methods for analysis and exploitation of protein structure, developing molecular graphics and modelling methods in the 1980s and building Structural Biology at York during the 1980s and 1990s. In 1997, he was a founding SAB member of what became Vernalis. Since 2001 he has split his time between Vernalis (fragment and structure based drug discovery) and York (fragment methods for chemical biology and industrial biotechnology). In addition, he works with UK Research Councils and consults with pharmaceutical and technology companies around the world.

    Roland Burli

    Senior Director, Head of Medicinal Chemistry, Astrazeneca
    Roland Burli

    Roland studied chemistry and did his PhD at the ETH (Zürich) on the synthesis and characterization of complex carbohydrate mimetics. He then did postdoctoral work at Caltech (USA) where he investigated sequence-specific DNA binding ligands. Prior to joining AstraZeneca, he worked in several small and large biotech companies (GeneSoft, Amgen, BioFocus) in the USA and the UK. He worked on many projects ranging from early hit identification to late-stage preclinical projects and candidate selection in several therapeutic areas. Over the past ~8 years, he has been focusing on new therapies for neurodegenerative diseases and neurological disorders.
     

    Tobias Gabriel

    Head, External Science & Drug Discovery, Novartis Institutes for BioMedical Research, Inc.
    Tobias Gabriel

    Tobias Gabriel is the Global Head of External Drug Discovery for Global Discovery Chemistry, Novartis Institutes for BioMedical Research.
    Prior to his current role Tobias was Head of Oncology Chemistry, Basel and Shanghai.
    Tobias joined Novartis eight years ago from Roche where he held positions of increasing responsibility in Medicinal Chemistry in Palo Alto and as Director of Research Strategy in Basel.
    Tobias studied Chemistry in Berlin and completed his Ph.D. in Organic Chemistry in Munich, followed by postdoctoral studies in nanotechnology at the Hebrew University of Jerusalem.
     

    Ulrich Schopfer

    Head of Integrated Target & Lead Discovery, Novartis
    Ulrich Schopfer

    Ulrich Schopfer is Site Head Basel, Chemical Biology & Therapeutics at the Novartis Institutes for BioMedical Research (NIBR). The department applies chemical biology and enabling technologies to discover novel targets, to prototype new drug modalities and to contribute drug candidates to the Novartis pipeline. Previously he held various roles in lead discovery involving both technology as well as portfolio responsibilities. He started his career at Novartis as medicinal chemist and project team leader of different discovery programs in Neuroscience. Ulrich Schopfer holds a PhD in chemistry and has authored over 40 publications and book chapters in the areas of chemical biology, lead discovery, medicinal chemistry, compound library management, and organic chemistry.

    Vivek Vishnudas

    Sr Vice President Drug discovery & Platform Sciences, Berg LLC
    Vivek Vishnudas

    In his role of Sr Vice President, Drug Discovery & Platform Sciences, Vivek Vishnudas, Ph.D., oversees the development of experimental therapeutics from conception and drug discovery to first-in-human studies. Drug-discovery programs are based on the novel disease targets identified through the use of Interrogative Biology®. Dr. Vishnudas leads an interdisciplinary team of drug-discovery scientists, biochemists and DMPK scientists to illuminate target biology & pharmacology, while working closely with regulatory, analytics and biomarker teams.
    Dr. Vishnudas manages the external R&D collaboration with industrial and academic partners, and aims to scale up Berg’s R&D therapeutics portfolio. He is a co-inventor of the Interrogative Biology® technology, and continues to spearhead development activities of “data-driven” technologies that enable drug discovery programs. His breadth of operations covers scientific leadership, strategic R&D initiatives and commercial and intellectual property strategies.
    Prior to moving to industry, Dr. Vishnudas was a research fellow in the Senator Paul D. Wellstone Center for Excellence in Muscular Dystrophy/BBRI, where he completed his postdoctoral training. Through his graduate school (University of Vermont) and postdoctoral fellowship, Vivek received extensive training in the field of muscle physiology and skeletal muscle diseases. Vivek has more than 10 U.S. and international patent applications that cover wide areas of metabolic disease, oncology and neurological indications.
    Dr. Vishnudas received a Master’s degree in Biochemistry from the National Dairy Research Institute (NDRI, ICAR India) and a Ph.D in Biology from the University of Vermont.

     

    Official Media Partner

    Supporters

    Workshops

    Artificial Intelligence in Drug Discovery
    Workshop

    Artificial Intelligence in Drug Discovery

    Copthorne Tara Hotel
    20th March 2019
    London, United Kingdom

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Drug Discovery 2019 Speaker Interview with Markus Queisser

    Download

    Drug Discovery 2019 Speaker Interview with Hassane Ratni

    Download

    Drug Discovery 2019 Speaker Interview with Tobias Gabriel

    Download

    Drug Discovery 2019 Speaker Interview with EDGAR JACOBY

    Download

    2019 POST CONFERENCE WORKSHOP

    Download

    Drug Discovery 2019 2-day Agenda

    Download

    Drug Discovery 2019 Brochure

    Download

    GSK - 2017 Conference Speaker Presentation

    Download

    Heptares Therapeutics - 2017 Conference Speaker Presentation

    Download

    Lilly - 2018 Conference Speaker Presentation

    Download

    Takeda - 2017 Conference Speaker Presentation

    Download

    Sanofi - 2018 Conference Speaker Presentation

    Download

    Roche - 2018 Conference Speaker Presentation

    Download

    GSK - 2018 Conference Speaker Presentation

    Download

    Ursula Egner 2018 Conference Speaker Presentation

    Download

    Media Partners


    Drug Target Review

    Official Media Partner
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Drug Discovery Today

    Official Media Partner
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.

    Media Partners


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    SciDoc Publishers

    Supporters
    http://www.scidoc.org

    SciDoc Publishers is a major source provider of e-journals in the field of Science, Technology and Medicine (STM). The nature of journals - Open Access and Peer-reviewed. We are aimed with a sole motive in making a mark in the field of Open Access, by propagating the knowledge to the scientific community. Our prime concern involves, the knowledge to reach millions of readers and give them access to scientific publications - online.


    IPI

    Supporters
    http://www.ipimediaworld.com

    IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    MedTube

    Supporters
    https://medtube.net/


    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out